Literature DB >> 1702077

Interaction of the cholinergic system and cholecystokinin in the regulation of endogenous and exogenous stimulation of pancreatic secretion in humans.

G Adler1, C Beglinger, U Braun, M Reinshagen, I Koop, A Schafmayer, L Rovati, R Arnold.   

Abstract

Pancreatic enzyme secretion is regulated in humans by the cholinergic system and by cholecystokinin (CCK). The interaction between both regulatory systems in response to exogenous and endogenous stimulation was analyzed in the present study using the cholinergic antagonist atropine and the CCK antagonist loxiglumide. A dose-dependent stimulation of pancreatic enzyme output was achieved either by duodenal perfusion of graded caloric loads or by IV infusion of increasing doses of cerulein. Prestimulated pancreatic secretion was inhibited by atropine and loxiglumide. Atropine furthermore almost completely blocked meal-stimulated pancreatic secretion, whereas loxiglumide caused 60% inhibition. The enzyme response to graded doses of exogenous CCK was significantly inhibited by atropine and loxiglumide. Plasma levels of CCK were not altered by atropine but increased with infusion of loxiglumide. This study supports the concept that pancreatic enzyme secretion is predominantly dependent on a cholinergic tone and that CCK modulates the enzyme-secretory response.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1702077     DOI: 10.1016/0016-5085(91)90227-c

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  24 in total

Review 1.  Pancreatic function tests: when to choose, what to use.

Authors:  W G Boeck; G Adler; T M Gress
Journal:  Curr Gastroenterol Rep       Date:  2001-04

Review 2.  Secretion and fluid transport mechanisms in the mammary gland: comparisons with the exocrine pancreas and the salivary gland.

Authors:  James L McManaman; Mary E Reyland; Edwin C Thrower
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-10       Impact factor: 2.673

Review 3.  Animal models of gastrointestinal and liver diseases. Animal models of acute and chronic pancreatitis.

Authors:  Xianbao Zhan; Fan Wang; Yan Bi; Baoan Ji
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-07-14       Impact factor: 4.052

4.  The changes in the rat parotid glands following total parenteral nutrition and pancreatico-biliary diversion are not mediated by cholecystokinin.

Authors:  J Axelson; B G Fan; B Ohlsson; J Rehfeld; M Ekelund; I Ihse
Journal:  Int J Pancreatol       Date:  1996-10

5.  M1-muscarinic mechanisms regulate interdigestive cycling of motor and secretory activity in human upper gut.

Authors:  D K Nelson; O Pieramico; G Dahmen; J E Dominguez-Muñoz; P Malfertheiner; G Alder
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

6.  Time-course of the pancreatic changes following long-term stimulation or inhibition of the CCK-A receptor.

Authors:  B Ohlsson; J Axelson; B Sternby; J F Rehfeld; I Ihse
Journal:  Int J Pancreatol       Date:  1995-08

7.  Influence of high-dose pancreatic enzyme treatment on pancreatic function in healthy volunteers.

Authors:  H Friess; J Kleeff; P Malfertheiner; M W Müller; K Homuth; M W Büchler
Journal:  Int J Pancreatol       Date:  1998-04

8.  Vagal afferent pathway mediates physiological action of cholecystokinin on pancreatic enzyme secretion.

Authors:  Y Li; C Owyang
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

9.  Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation.

Authors:  M A Nauck; M Büsing; C Orskov; E G Siegel; J Talartschik; A Baartz; T Baartz; U T Hopt; H D Becker; W Creutzfeldt
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

10.  Mechanism of galanin's inhibitory action on pancreatic enzyme secretion: modulation of cholinergic transmission--studies in vivo and in vitro.

Authors:  K H Herzig; G Brunke; I Schön; M Schäffer; U R Fölsch
Journal:  Gut       Date:  1993-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.